Search

Introduction HIV-1 viral Load (VL) testing is recommended for the monitoring of antiretroviral treatment. Dried Blood Spots (DBS) are an effective sample type in resource limited settings, where safe phlebotomy and reliable shipping are hard to guarantee. In HIV high burden countries, high throughput assays can improve access to testing services. The Hologic Aptima HIV-1 Quant Dx Assay (Aptima Assay) is a high throughput assay that runs on the CE-IVD approved Panther platform. The objectives of this study were to assess the performance characteristics of Aptima for VL monitoring using plasma and venous DBS specimens and to determine the stability of HIV-1 RNA in DBS. Materials and methods This was a cross-sectional study of 2227 HIV infected adults visiting health facilities in Nairobi and Busia, Kenya. Each provided a venous blood sample; plasma was prepared from 1312 samples while paired DBS samples and plasma were prepared from the remaining 915 samples. The agreement between the Aptima assay and the Abbott RealTime HIV-1 Assay (Abbott RT) was analysed by comparing the HIV-1 VL in both assays at the medical decision point of 1000 copies/mL. To assess stability of HIV-1 RNA in DBS, VL in DBS spotted on day 0 were compared with that from the same DBS card after 21 days of storage at room temperature. Results Overall, 436 plasma samples had quantifiable results in both Aptima and Abbott RT. The agreement between the two assays at 1000 copies/mL was 97.48% with a Pearson’s correlation coefficient (r) of 0.9589 and gave a mean bias of 0.33 log copies/mL on Bland-Altman analysis. For fresh DBS, the agreement in both assays was 94.64% at 1000 copies/mL, with an r of 0.8692 and a mean bias of 0.35 log copies/mL. The overall agreement between DBS tested in Aptima on day 0 versus day 21 was 95.71%, with a mean bias of -0.154. Conclusion The Aptima HIV-1 Quant Dx assay is an accurate test for VL monitoring of HIV-1 using DBS and plasma sample types in Kenya.

Quantification of HIV-1 RNA is essential for clinical management of HIV patients. The limited throughput and significant hands-on time required by most HIV Viral load (VL) tests makes it challenging for laboratories with high test volume, to turn around patient results quickly. The Hologic Aptima HIV-1 Quant Dx Assay (Aptima), has the potential to alleviate this burden as it is high throughput and fully automated. This assay is validated for both plasma and dried blood spots (DBS), which are commonly used in resource limited settings. The objective of this study was to compare the performance of Aptima to Abbott RealTime HIV-1 Assay (Abbott RT), which was used as reference. This was a cross-sectional prospective study where HIV VL in finger stick (FS) DBS, venous blood (VB) DBS and plasma, collected from 258 consenting adults visiting 5 medical facilities in Kenya, Africa were tested in Aptima. The results were compared to plasma VL in Abbott RT at the medical decision point (MDP) of 1000 copies/mL and across Aptima assay range. The total agreement at MDP between plasma HIV VL in Abbott RT and plasma, FS and VB DBS tested in Aptima were 97.7%, 92.2% and 95.3% respectively with kappa statistic of 0.95, 0.84 and 0.90. The positive and negative agreement for all 3 sample types were >92%. Regression analysis between VL in Abbott RT plasma and various sample types tested in Aptima had a Pearson’s correlation coefficient ≥0.91 with systematic bias of < 0.20 log copies/mL on Bland-Altman analysis. The high level of agreement in Aptima HIV VL results for all 3 sample types with Abbott RT plasma VL along with the high throughput, complete automation, and ease of use of the Panther platform makes Aptima a good option for HIV VL monitoring for busy laboratories with high volume of testing.

Background Early infant diagnosis (EID) of HIV-1 exposed infants enables timely initiation of antiretroviral therapy (ART), thereby allowing early diagnosis and treatment to slow disease progression and reduce mortality. Turn-around time to results, partially caused by low to medium throughput technology, remains a hindrance to early treatment. A major solution to this challenge is to incorporate high throughput and accurate technologies in the testing process. The Hologic Aptima Quant Dx Assay (Aptima) is a CE marked Real-Time TMA assay running on the high throughput Panther system. Objectives The objective of this study was to evaluate the performance of Aptima for EID using dried blood spots. Study design This was a cross-sectional prospective study of 2,048 infants seeking HIV services from health facilities in Western Kenya, Africa. Capillary Dried Blood Spot samples DBS were collected from infants with the consent of their mothers. The qualitative performance of Aptima was compared with the Roche COBAS Ampliprep/ COBAS Taqman HIV-1 Qualitative Test v2.0 (CAP/CTM), using these DBS. Demographic information of the participants was also collected. Results A total of 1,975 successful comparisons between the two platforms were included in the analysis. The overall agreement between the assays was 99.65 %. The sensitivity and specificity of Aptima was 95.24 % (95 % CI 88.40–98.19 %) and 99.84 % (95 % CI 99.49–99.92 %) respectively. Conclusions Aptima assay has performance characteristics that are comparable to those of the Roche CAP/CTM for qualitative testing on DBS taken from infants. The two assays can therefore be used interchangeably for Early Infant Diagnosis of HIV.

Quantitation of the HIV-1 viral load in plasma is the current standard of care for clinical monitoring of HIV-infected individuals undergoing antiretroviral therapy. This study evaluated the analytical and clinical performances of the Aptima HIV-1 Quant Dx assay (Hologic, San Diego, CA) for monitoring viral load by using 277 well-characterized subtype samples, including 171 cultured virus isolates and 106 plasma samples from 35 countries, representing all major HIV subtypes, recombinants, and circulating recombinant forms (CRFs) currently in circulation worldwide. Linearity of the Aptima assay was tested on each of 6 major HIV-1 subtypes (A, B, C, D, CRF01_AE, and CRF02_AG) and demonstrated an R 2 value of ≥0.996. The performance of the Aptima assay was also compared to those of the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 v.2 (CAP/CTM) and Abbott m2000 RealTime HIV-1 (RealTime) assays on all subtype samples. The Aptima assay values averaged 0.21 log higher than the CAP/CTM values and 0.30 log higher than the RealTime values, and the values were >0.4 log higher than CAP/CTM values for subtypes F and G and than RealTime values for subtypes C, F, and G and CRF02_AG. Two samples demonstrated results with >1-log differences from RealTime results. When the data were adjusted by the average difference, 94.9% and 87.0% of Aptima results fell within 0.5 log of the CAP/CTM and RealTime results, respectively. The linearity and accuracy of the Aptima assay in correctly quantitating all major HIV-1 subtypes, coupled with the completely automated format and high throughput of the Panther system, make this system well suited for reliable measurement of viral load in the clinical laboratory.

Detection of acute HIV infection is critical for HIV public health and diagnostics. Clinical fourth-generation antigen (Ag)/antibody (Ab) combination (combo) and p24 Ag immunoassays have enhanced detection of acute infection compared to Ab-alone assays but require ongoing evaluation with currently circulating diverse subtypes. Genetically and geographically diverse HIV clinical isolates were used to assess clinical HIV diagnostic, blood screening, and next-generation assays. Three-hundred-member panels of 20 serially diluted well-characterized antibody-negative HIV isolates for which the researchers were blind to the results (blind panels) were distributed to manufacturers and end-user labs to assess the relative analytic sensitivity of currently approved and preapproved clinical HIV fourth-generation Ag/Ab combo or p24 Ag-alone immunoassays for the detection of diverse subtypes. The limits of detection (LODs) of virus were estimated for different subtypes relative to confirmed viral loads. Analysis of immunoassay sensitivity was benchmarked against confirmed viral load measurements on the blind panel. On the basis of the proportion of positive results on 300 observations, all Ag/Ab combo and standard sensitivity p24 Ag assays performed similarly and within half-log LODs, illustrating the similar breadth of reactivity and diagnostic utility. Ultrasensitive p24 Ag assays achieved dramatically increased sensitivities, while the rapid combo assays performed poorly. The similar performance of the different commercially available fourth-generation assays on diverse subtypes supports their use in broad geographic settings with locally circulating HIV clades and recombinant strains. Next-generation preclinical ultrasensitive p24 Ag assays achieved dramatically improved sensitivity, while rapid fourth-generation assays performed poorly for p24 Ag detection.

The search for a cure for HIV infection has highlighted the need for increasingly sensitive and precise assays to measure viral burden in various tissues and body fluids. We describe the application of a standardized assay for HIV-1 RNA in multiple specimen types. The fully automated Aptima HIV-1 Quant Dx assay (Aptima assay) is FDA cleared for blood plasma HIV-1 RNA quantitation. In this study, the Aptima assay was applied for the quantitation of HIV RNA in peripheral blood mononuclear cells (PBMCs;n= 72), seminal plasma (n= 20), cerebrospinal fluid (CSF;n= 36), dried blood spots (DBS;n= 104), and dried plasma spots (DPS;n= 104). The Aptima assay was equivalent to or better than commercial assays or validated in-house assays for the quantitation of HIV RNA in CSF and seminal plasma. For PBMC specimens, the sensitivity of the Aptima assay in the detection of HIV RNA decayed as background uninfected PBMC counts increased; proteinase K treatment demonstrated some benefit in restoring signal at higher levels of background PBMCs. Finally, the Aptima assay yielded 100% detection rates of DBS in participants with plasma HIV RNA levels of ≥35 copies/ml and 100% detection rates of DPS in participants with plasma HIV RNA levels of ≥394 copies/ml. The Aptima assay can be applied to a variety of specimens from HIV-infected subjects to measure HIV RNA for studies of viral persistence and cure strategies. It can also detect HIV in dried blood and plasma specimens, which may be of benefit in resource-limited settings.

Background Quantitation of HIV-RNA is critically important for diagnosis, prognosis, treatment, monitoring and assessment of infectivity in HIV-1 infection. The objective of this study was to assess performance characteristics of the Aptima HIV-1 Quant Dx assay (Aptima), a new transcription mediated amplification (TMA), fully integrated and automated assay from Hologic Inc., San Diego, CA, USA. The analytical sensitivity, analytical specificity, precision and detection of HIV-1 subtypes were tested based on commercially available international standards or panels. A selected group of 244 anti-HIV-1 (+) plasma samples was used for comparison with Roche COBAS Ampliprep/COBAS TaqMan HIV- 1 test v2.0 (Roche CAP/CTM), (Roche Molecular Systems, Pleasanton, CA). Results The 50 and 95 % limit of detection were estimated at 4.9 (95 % CI 3.9–5.7) and 17.6 (15.2–21.2) IU/mL respectively. The specificity was found 99.83 (99.06–99.97) %. The standard deviations and coefficient of variations for panels with 50 and 100 copies/mL (1.7 and 2 log copies/mL) were 0.14 log copies/mL (8.67 %CV) and 0.18 log copies/mL (9.91 %CV) respectively. The detection rate for Aptima and Roche assays was 220/244 (90.2 %) and 217/244 (88.9 %) respectively. Conclusion The Aptima assay is a sensitive, specific, precise and accurate test for measuring HIV-1 viral loads and for the detection of HIV-1 infections.

The Aptima® HIV-1 Quant Dx Assay is a fully automated assay on the Panther system. It is based on Transcription- Mediated Amplification and real time detection technologies. This assay is intended for monitoring HIV-1 viral load in plasma specimens and for the detection of HIV-1 in plasma and serum specimens. Nine-hundred and seventy nine specimens selected at random from routine testing at St Thomas' Hospital, London were anonymised and used to compare the performance of the Aptima HIV-1 Quant Dx assay and Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0. Two-hundred and thirty four specimens gave quantitative HIV-1 viral load results in both assays. The quantitative results reported by the Aptima Assay were comparable to those reported by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 with a linear regression slope of 1.04 and an intercept on -0.097. The Aptima assay detected HIV-1 in more samples than the COBAS assay. This was not due to lack of specificity of the Aptima assay because this assay gave 99.83% specificity on testing plasma specimens from 600 HIV-1 negative individuals. To understand the reason for this higher detection rate a side-by-side comparison of low level panels made from the HIV-1 3rd international standard (NIBSC10/152) and clinical samples of various subtypes were tested in both assays. The Aptima assay was more sensitive than the COBAS assay. The good sensitivity, specificity and agreement with other commercial assays make the HIV-1 Quant Dx Assay appropriate for both viral load monitoring and detection of HIV-1 infections., {"references": ["Mellors, J.W., C. R. Rinaldo, Jr, P. Gupta , R. M. White, J. A. Todd , L.\nA. Kingsley 1996. Prognosis in HIV-1 infection predicted by the\nquantity of virus in plasma. Science 272:1167\u20131170.", "Wei X., S. K.Ghosh, M.E. Taylor , V. A. Johnson , E. A. Emini, P.\nDeutsch , J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. H. Hahn. 1995.\nViral dynamics in human immunodeficiency virus type 1 infection.\nNature 373:117\u2013122.", "Perelson A.S., A. U. Neumann, M. Markowitz, J. M. Leonard, D.D. Ho\n1996. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan,\nand viral generation time. Science 271:1582\u20131586", "O'Brien, W. A., P. M. Hartigan, D. Martin, J. Esinhart, A. Hill, S.\nBenoit, M. Rubin, M. S. Simberkoff, and J. D. Hamilton. 1996. Changes\nin plasma HIV-1 RNA and CD4 lymphocyte counts and the risk of\nprogression to AIDS. Veterans Affairs Cooperative Study Group on\nAIDS. N. Engl. J. Med. 334:426-431.", "Welles, S. L., J. B. Jackson, B. Yen-Lieberman, L. Demeter, A. J.\nJapour, L. M. Smeaton, V. A. Johnson, D. R. Kuritzkes, R. T. P. A.\nReichelderfer, D. D. Richman, R. Reichman, M. Fischl, R. Dolin, R. W.\nCoombs, J. O. Kahn, C. McLaren, J. Todd, S. Kwok, and C. S.\nCrumpacker. 1996. Prognostic value of plasma human\nimmunodeficiency virus type I (HIV-1) RNA levels in patients with\nadvanced HIV-1 disease and with little or no zidovudine therapy. AIDS\nClinical Trials Group Protocol 116A/116B/117 Team. J. Infect. Dis.\n174:696-703.", "Coombs, R. W., S. L. Welles, C. Hooper, P. S. Reichelderfer, R. T.\nD'Aquila, A. J. Japour, V. A. Johnson, D. R. Kuritzkes, D. D. Richman,\nS. Kwok, J. Todd, J. B. Jackson, V. DeGruttola, C. S. Crumpacker, and\nJ. Kahn. 1996. Association of plasma human immunodeficiency virus\nType I RNA level with risk of clinical progression in patients with\nadvanced infection. AIDS Clinical Trials Group (ACTG) 116B/117\nStudy Team. ACTG Virology Committee Resistance and HIV-1 RNA\nWorking Groups. J. Infect. Dis. 174:704-712.", "Human immunodeficiency virus type 1 RNA level and CD4 count as\nprognostic markers and surrogate end points: a meta-analysis. HIV\nSurrogate Marker Collaborative Group. AIDS Res Hum Retroviruses.\n2000;16 (12):1123-1133.", "Brenner B.G., M. Roger , J.P. Routy, D. Moisi, M. Ntemgwa, C. Matte,\nJ. G. Baril, R. Thomas, D.Rouleau, J. Bruneau, R. Leblanc, M. Legault,\nC. Tremblay, H. Charest, M. A. Wainberg. Quebec Primary HIV\nInfection Study Group. 2007 High rates of forward transmission events\nafter acute/early HIV-1 infection. J Infect Dis;195: 951-959.", "Cohen M.S., Y.Q. Chen, M. McCauley, T. Gamble, M. C. Hosseinipour,\nN. Kumarasamy, J.G. Hakim, J. Kumwenda, B. Grinsztejn, J.H.S.\nPilotto, S.V. Godbole, S. Mehendale, S. Chariyalertsak, B.R. Santos,\nK.H. Mayer, I.F. Hoffman , S.H. Eshleman, E. Piwowar-Manning, L.\nWang, J. Makhema, L.A. Mills, G. de Bruyn, I. Sanne, J. Eron, J.\nGallant, D. Havlir, S. Swindells, H. Ribaudo, V. Elharrar, D. Burns, T.\nE. Taha, K. Nielsen-Saines, D. Celentano, M. Essex, and T.R. Fleming\nfor the HPTN 052 Study Team Prevention of HIV-1 infection with early\nantiretroviral therapy. 2011 Prevention of HIV-1 Infection with Early\nAntiretroviral Therapy. N Engl J Med.; 365(6):493-505.\n[10] WHO. 2013. Consolidated guidelines on the use of antiretroviral drugs\nfor treating and preventing HIV infection: recommendations for a public\nhealth approach. World Health Organization, Geneva, Switzerland.\nhttp://www.who.int/hiv/pub/guidelines/arv2013/en/\n[11] WHO. 2014. March 2014 supplement to the 2013 consolidated\nguidelines on the use of antiretroviral drugs for treating and preventing\nHIV infection: recommendations for a public health approach. World\nHealth Organization, Geneva, Switzerland. http://www.who.int/hiv/pub/\nguidelines/arv2013/arvs2013upplement_march2014/en/\n[12] Bennett B, S. Fordan, L. Haddock-Morilla, M. Rowlinson 2013 HIV\nSingle staging algorithm: integration and maximization of resources by\nreducing time between HIV diagnosis and treatment. J. Clin.Virol\n58(1):34-37.\n[13] Styer L.S., T.J. Sullivan, M.M. Parker 2011. Evaluation of an alternative\nsupplemental testing strategy for HIV diagnosis by retrospective\nanalysis of clinical HIV testing data Journal Clin. Virol 52 (1): S35\u2013 40\n[14] Amendola A., P. Marsella, M. Boisi, F. Forbici, C. Angeletti, M. R.\nCapobianchi. 2014. Ability of two commercially available assays\n(Abbott RealTime HIV-1 and Roche AmpliPrep/Cobas Taqman HIV-1\nVersion 2.0) to quantify low HIV-1 RNA levels (

BackgroundSeparate assays are available for diagnosis and viral load (VL) monitoring of HIV-1. Studies have shown that using a single test for both confirmatory diagnosis and VL increases linkage to care.ObjectiveTo validate a single assay for both diagnosis and VL monitoring of HIV-1 on the fully automated Panther platform.Study designValidate the assay by assessing specificity, sensitivity, subtype detection, seroconversion, reproducibility and linearity. Also assess diagnostic agreement with the Procleix® Ultrio Elite™ discriminatory assay (Procleix), and agreement of VL results (method comparison) with Ampliprep/COBAS TaqMan HIV-1 version 2.0 (CAP/CTM), using clinical samples.ResultsThe assay was specific (100%) and sensitive with a 95% limit of detection of 12 copies/mL with the 3rd WHO standards. Aptima detected HIV in seroconversion panels 6 and 11 days before p24 antigen and antibody tests, respectively. Diagnostic agreement with Procleix, was 100%. Regression analysis showed good agreement of VL results between Aptima and CAP/CTM with a slope of 1.02, intercept of 0.07, and correlation coefficient (R2) of 0.97. Aptima was more sensitive than CAP/CTM. Equivalent quantification was seen on testing clinical samples and isolates belonging to HIV group M, N, O and P and commercially available subtype panels. Assay results were linear (R2 0.9994) with standard deviation of